GENDER AND ABUSABLE PRESCRIPTION DRUGS

这项研究的目的是提供一个更好的了解滥用 处方药的潜力。 以性别问题为重点框架， 一项研究将审查使用可能滥用的药物的人群的二级数据。 医疗用途、非医疗用途、滥用和依赖性处方药 contexts. 虽然有证据表明男性更有可能滥用 处方药，其他研究已经证明，妇女面临更大的 接触可滥用的处方药。 通过关注性别 差异，本研究将全面考察预测因素 滥用处方药的医疗和非医疗用途以及如何使用 这些药物可能会导致不良反应和依赖性增加。 的 这项研究的主要目的是了解性别差异， 四类滥用处方的使用、滥用和依赖 药物--止痛药、镇静剂、镇静催眠药和兴奋剂。 到 为了实现这一目标，研究将解决以下具体问题： 目的：（1）检查与医疗有关的性别和其他因素 滥用处方药的使用和非医疗使用;（2）非医疗使用 使用者，确定性别与药物不良反应的关系 使用，包括对健康状况和社会功能的影响;（3） 非医疗使用者，确定性别与物质的关联 （4）检查治疗开始时的性别差异， （5）研究药物滥用的性别差异; 治疗方式、治疗服务和出院状态。 分析 将利用三个二级数据库：（a）国家医疗数据库， 支出调查;（B）全国家庭药物调查 滥用（NHDA）;和（c）药物服务研究调查（DSRS）。 结果 这项研究将为进一步研究提供基础。 处方药的医疗和非医疗使用的预测因素， 并使决策者更好地了解性别平等如何 对非医疗处方药的使用构成不同的风险， 发展中国家必须考虑性别差异 预防和治疗策略。

The intent of this study is to provide a greater understanding of the abuse potential of prescription drugs. Using gender as a focusing framework, the study will examine secondary data of populations using potentially abusable prescription drugs in medical use, nonmedical use, abuse, and dependence contexts. While evidence suggests that men are more likely to abuse prescription drugs, other studies have documented that women face greater exposure to abusable prescription drugs. By concentrating on gender differences, this study will comprehensively examine the factors predicting the medical and nonmedical use of abusable prescription drugs and how use of these drugs may lead to increased adverse effects and dependence. The primary objective of this study is to understand gender differences in the use, abuse, and dependence of four categories of abusable prescription drugs -- analgesics, tranquilizers, sedative-hypnotics, and stimulants. To accomplish the objective, the study will address the following specific aims: (1) Examine gender and other factors associated with the medical use and non medical use of abusable prescription drugs; (2) For nonmedical users, determine the association of gender with adverse effects of drug use, including effects on health status and social functioning; (3) For nonmedical users, determine the association of gender with substance dependency; (4) Examine gender differences in entry to treatment for prescription drug abuse; and (5) Examine gender differences in the use of treatment modalities, treatment services, and discharge status. Analyses will draw on three secondary data bases (a) the National medical Expenditures Survey (NAMES); (b) the National Household Survey on Drug Abuse (NHSDA); and (c) the Drug Services Research Survey (DSRS). Findings from this research will provide a basis for further investigations of predictors of the medical and non-medical use of prescription drugs, as well as provide policy makers with an increased understanding of how gender poses a differential risk for non-medical prescription drug use and the necessity of considering gender differences in the development of prevention and treatment strategies.